Comparative analysis of sFRP4 expression across various breast cancer subclasses revealed significantly higher levels in healthy volunteers compared to patients with TNBC and HER2 receptor-positive BC, as shown in Fig 1B. This evidence concerns the gene SFRP4 and breast carcinoma.